Literature DB >> 25829327

Discoidin domain receptor-1 and periostin: new players in chronic kidney disease.

Carlo Alfieri1, Panagiotis Kavvadas2, Paola Simonini3, Masami Ikehata4, Jean Claude Dussaule2, Christos E Chadjichristos2, Maria Pia Rastaldi4, Piergiorgio Messa3, Christos Chatziantoniou2.   

Abstract

The incidence and prevalence of chronic kidney disease represents an important problem for public health. In renal diseases, the main histologic alterations derive from the development of renal fibrosis which results from the loss of the balance between pro- and anti-fibrotic factors. Tyrosine kinase receptors (RTKs) and matricellular proteins (MPs) are nowadays studied as potential modulators of renal injury. RTKs regulate cell cycle, migration, metabolism and cellular differentiation. Discoidin domain receptor-1 (DDR-1) is an RTK that has been extensively studied in cancer, and lung and renal diseases. It modulates inflammatory recruitment, extracellular matrix deposition and fibrosis; in renal diseases, it appears to act independently of the underlying disease. MPs regulate cell-matrix interactions and matrix accumulation, cellular adhesion and migration, and expression of inflammatory cells. Periostin is an MP, mainly studied in bone, heart, lung and cancer. Several studies demonstrated that it mediates cell-matrix interactions, migration of inflammatory cells and development of fibrosis. Recently, it has been reported in several nephropathies. In this review, we discuss the potential pathological roles of DDR-1 and periostin focussing on the kidney in both experimental models and human diseases.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  discoidin domain receptor-1; matricellular proteins; periostin; renal fibrosis; tyrosine kinase receptors

Mesh:

Substances:

Year:  2015        PMID: 25829327      PMCID: PMC4832988          DOI: 10.1093/ndt/gfv074

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  49 in total

1.  Pirfenidone for diabetic nephropathy.

Authors:  Kumar Sharma; Joachim H Ix; Anna V Mathew; Monique Cho; Axel Pflueger; Stephen R Dunn; Barbara Francos; Shoba Sharma; Bonita Falkner; Tracy A McGowan; Michael Donohue; Satish Ramachandrarao; Ronghui Xu; Fernando C Fervenza; Jeffrey B Kopp
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 2.  Imatinib: novel treatment of immune-mediated kidney injury.

Authors:  Eric Wallace; Leslie Gewin
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

3.  Urine periostin as a biomarker of renal injury in chronic allograft nephropathy.

Authors:  B Satirapoj; R Witoon; P Ruangkanchanasetr; P Wantanasiri; M Charoenpitakchai; P Choovichian
Journal:  Transplant Proc       Date:  2014 Jan-Feb       Impact factor: 1.066

4.  EMI, a novel cysteine-rich domain of EMILINs and other extracellular proteins, interacts with the gC1q domains and participates in multimerization.

Authors:  R Doliana; S Bot; P Bonaldo; A Colombatti
Journal:  FEBS Lett       Date:  2000-11-03       Impact factor: 4.124

5.  Fibrosis, regeneration, and aging: playing chess with evolution.

Authors:  Vicente E Torres; Edward B Leof
Journal:  J Am Soc Nephrol       Date:  2011-07-14       Impact factor: 10.121

6.  Periostin induces intracellular cross-talk between kinases and hyaluronan in atrioventricular valvulogenesis.

Authors:  Shibnath Ghatak; Suniti Misra; Russell A Norris; Ricardo A Moreno-Rodriguez; Stanley Hoffman; Robert A Levine; Vincent C Hascall; Roger R Markwald
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

7.  Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.

Authors:  Mingshan Gao; Lei Duan; Jinfeng Luo; Lianwen Zhang; Xiaoyun Lu; Yan Zhang; Zhang Zhang; Zhengchao Tu; Yong Xu; Xiaomei Ren; Ke Ding
Journal:  J Med Chem       Date:  2013-04-10       Impact factor: 7.446

8.  Inhibition of periostin expression protects against the development of renal inflammation and fibrosis.

Authors:  Mouna Mael-Ainin; Ahmed Abed; Simon J Conway; Jean-Claude Dussaule; Christos Chatziantoniou
Journal:  J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 10.121

9.  Periostin: a matricellular protein involved in peritoneal injury during peritoneal dialysis.

Authors:  Niko Braun; Kontheari Sen; M Dominik Alscher; Peter Fritz; Martin Kimmel; Johann Morelle; Eric Goffin; Achim Jörres; Rudolf P Wüthrich; Clemens D Cohen; Stephan Segerer
Journal:  Perit Dial Int       Date:  2013-02-01       Impact factor: 1.756

Review 10.  Targeting the PDGF signaling pathway in tumor treatment.

Authors:  Carl-Henrik Heldin
Journal:  Cell Commun Signal       Date:  2013-12-20       Impact factor: 5.712

View more
  8 in total

1.  Novel markers of graft outcome in a cohort of kidney transplanted patients: a cohort observational study.

Authors:  C Alfieri; A Regalia; G Moroni; D Cresseri; F Zanoni; M Ikehata; P Simonini; M P Rastaldi; G Tripepi; C Zoccali; C Chatziantoniou; Piergiorgio Messa
Journal:  J Nephrol       Date:  2019-01-10       Impact factor: 3.902

2.  Periostin promotes liver fibrogenesis by activating lysyl oxidase in hepatic stellate cells.

Authors:  Pradeep Kumar; Tekla Smith; Reben Raeman; Daniel M Chopyk; Hannah Brink; Yunshan Liu; Todd Sulchek; Frank A Anania
Journal:  J Biol Chem       Date:  2018-06-25       Impact factor: 5.157

3.  Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy.

Authors:  Inès Jadot; Vanessa Colombaro; Blanche Martin; Isabelle Habsch; Olivia Botton; Joëlle Nortier; Anne-Emilie Declèves; Nathalie Caron
Journal:  PLoS One       Date:  2017-08-23       Impact factor: 3.240

Review 4.  Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.

Authors:  Terry King-Wing Ma; Stephen P McAdoo; Frederick Wai Keung Tam
Journal:  Nephrol Dial Transplant       Date:  2017-01-01       Impact factor: 5.992

5.  Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime.

Authors:  Solange Moll; Yukari Yasui; Ahmed Abed; Takeshi Murata; Hideaki Shimada; Akira Maeda; Naoshi Fukushima; Masakazu Kanamori; Sabine Uhles; Laura Badi; Thomas Cagarelli; Ivan Formentini; Faye Drawnel; Guy Georges; Tobias Bergauer; Rodolfo Gasser; R Daniel Bonfil; Rafael Fridman; Hans Richter; Juergen Funk; Marcus J Moeller; Christos Chatziantoniou; Marco Prunotto
Journal:  J Transl Med       Date:  2018-06-01       Impact factor: 5.531

6.  Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation.

Authors:  William A Denny; Jack U Flanagan
Journal:  Biomolecules       Date:  2021-11-10

7.  DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome.

Authors:  Hans Richter; Alexander L Satz; Marc Bedoucha; Bernd Buettelmann; Ann C Petersen; Anja Harmeier; Ricardo Hermosilla; Remo Hochstrasser; Dominique Burger; Bernard Gsell; Rodolfo Gasser; Sylwia Huber; Melanie N Hug; Buelent Kocer; Bernd Kuhn; Martin Ritter; Markus G Rudolph; Franziska Weibel; Judith Molina-David; Jin-Ju Kim; Javier Varona Santos; Martine Stihle; Guy J Georges; R Daniel Bonfil; Rafael Fridman; Sabine Uhles; Solange Moll; Christian Faul; Alessia Fornoni; Marco Prunotto
Journal:  ACS Chem Biol       Date:  2018-12-16       Impact factor: 5.100

8.  Periostin interaction with discoidin domain receptor-1 (DDR1) promotes cartilage degeneration.

Authors:  Tianzhen Han; Paolo Mignatti; Steven B Abramson; Mukundan Attur
Journal:  PLoS One       Date:  2020-04-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.